Micro- and nanoparticulates

Adv Drug Deliv Rev. 2005 Dec 13;57(14):2047-52. doi: 10.1016/j.addr.2005.09.006. Epub 2005 Nov 17.

Abstract

Objectives: Pharmacotherapeutics has begun to play an increasingly important role in the management of patients with neovascular age-related macular degeneration (AMD). Because micro- and nano-particulates are currently being evaluated as a potential drug-delivery option for AMD patients, the purpose of this analysis was to describe how micro- and nano-particulates have been used experimentally and what their potential clinical applications may be.

Findings: Micro- and nano-particulates have been used primarily on a pre-clinical basis as new drug-delivery devices in experimental models of neovascular AMD.

Conclusions: It is likely that micro- and nano-particulates will become an important component of targeted clinical pharmacotherapeutics in patients with neovascular AMD.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / chemistry
  • Anti-Inflammatory Agents / pharmacokinetics
  • Anti-Inflammatory Agents / therapeutic use
  • Budesonide / chemistry
  • Budesonide / pharmacokinetics
  • Budesonide / therapeutic use
  • Delayed-Action Preparations / chemistry
  • Delayed-Action Preparations / pharmacokinetics
  • Delayed-Action Preparations / therapeutic use
  • Drug Carriers / chemistry
  • Drug Delivery Systems / methods
  • Eye Diseases / drug therapy
  • Eye Diseases / metabolism
  • Humans
  • Macular Degeneration / drug therapy*
  • Microspheres*
  • Nanostructures / chemistry*
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / metabolism

Substances

  • Anti-Inflammatory Agents
  • Delayed-Action Preparations
  • Drug Carriers
  • Budesonide